Aardvark Therapeutics, Inc.
Public company- Headquarters
- SAN DIEGO, California
- Ticker
- AARD
- CIK
- 0001774857
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| Class II directorDavid (Zhongwei) Zhang, Ph.D., MBA | Oct 8, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- ACADIA PHARMACEUTICALS INC
Executive Vice President, Head of Research and Development departs: Elizabeth H.Z. Thompson, Ph.D.
- KYNTRA BIO, INC.
Class III director appointed: Andrew E. Singer, MBA
- BIOMARIN PHARMACEUTICAL INC
WARN notice: Novato, CA
- CORCEPT THERAPEUTICS INC
President of Corcept Endocrinology departs: Sean Maduck
- Executive appointment
Class II director appointed: David (Zhongwei) Zhang, Ph.D., MBA
David (Zhongwei) Zhang, Ph.D., MBA was named Class II director of Aardvark Therapeutics, Inc., effective October 7, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 8, 2026Role: Class II director
Only one public record so far. We add events as soon as a new filing lands; watch Aardvark Therapeutics, Inc. to get them in your digest.
Last verified Nov 8, 2026